Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer
Publication Date: August 8, 2016
Key Points
Key Points
Nearly 75% of women with ovarian cancer are diagnosed with advanced stage disease (International Federation of Gynecology and Obstetrics [FIGO] IIIC or IV) at presentation.
Recently two randomized clinical trials (RCTs) demonstrated that neoadjuvant chemotherapy (NACT) was noninferior to primary cytoreductive surgery (PCS) with respect to progression-free and overall survival and resulted in a lower incidence of treatment-related morbidity and mortality.
However, both trials have been criticized because the median overall survival, mean operative time, and rates of optimal cytoreduction were lower than expected.
This Guideline provides guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
Recently two randomized clinical trials (RCTs) demonstrated that neoadjuvant chemotherapy (NACT) was noninferior to primary cytoreductive surgery (PCS) with respect to progression-free and overall survival and resulted in a lower incidence of treatment-related morbidity and mortality.
However, both trials have been criticized because the median overall survival, mean operative time, and rates of optimal cytoreduction were lower than expected.
This Guideline provides guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
Assessment
...Assessment...
...with suspected stage IIIC or IV invasive epitheli...
...linical evaluation should include a computed to...
Treatment
...Treatment...
...Factors for Perioperative Morbidity or Mortality...
...high perioperative risk profile or a low likeliho...
...sions that women are not eligible...
...r women who are fit for PCS, with potentia...
...or women with a high likelihood of achieving cyto...
...or women who are fit for PCS but are deemed unlike...
...delivered, all patients should hav...
...a platinum/taxane doublet is recommended. ( EB ,...
...ted surgery following three or four cy...
...ogressive disease on NACT have a poor prognos...
...Evaluation and Treatment of Women With Suspected...